MX2014004326A - Anticuerpos a cd1d. - Google Patents

Anticuerpos a cd1d.

Info

Publication number
MX2014004326A
MX2014004326A MX2014004326A MX2014004326A MX2014004326A MX 2014004326 A MX2014004326 A MX 2014004326A MX 2014004326 A MX2014004326 A MX 2014004326A MX 2014004326 A MX2014004326 A MX 2014004326A MX 2014004326 A MX2014004326 A MX 2014004326A
Authority
MX
Mexico
Prior art keywords
antibodies
cd1d
antigen binding
binding portions
bind
Prior art date
Application number
MX2014004326A
Other languages
English (en)
Spanish (es)
Inventor
Andrew James Pow
Lynn Dorothy Poulton
Adam Clarke
Debra Tamvakis
George Kopsidas
Anthony Gerard Doyle
Matthew Pollard
Johathan Kannan Nambiar
Huseyin Mustafa
Original Assignee
Teva Pharmaceuticals Australia Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2011904190A external-priority patent/AU2011904190A0/en
Application filed by Teva Pharmaceuticals Australia Pty Ltd filed Critical Teva Pharmaceuticals Australia Pty Ltd
Publication of MX2014004326A publication Critical patent/MX2014004326A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2014004326A 2011-10-14 2012-10-15 Anticuerpos a cd1d. MX2014004326A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161547307P 2011-10-14 2011-10-14
AU2011904190A AU2011904190A0 (en) 2011-10-14 Antibodies to CD1d
PCT/AU2012/001247 WO2013053021A1 (en) 2011-10-14 2012-10-15 ANTIBODIES TO CD1d

Publications (1)

Publication Number Publication Date
MX2014004326A true MX2014004326A (es) 2014-09-25

Family

ID=48081279

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014004326A MX2014004326A (es) 2011-10-14 2012-10-15 Anticuerpos a cd1d.

Country Status (14)

Country Link
US (1) US20140286957A1 (https=)
EP (1) EP2766042A4 (https=)
JP (1) JP2015502915A (https=)
KR (1) KR20140108520A (https=)
CN (1) CN104144700B (https=)
AU (1) AU2012323781B8 (https=)
BR (1) BR112014008691A2 (https=)
CA (1) CA2850961A1 (https=)
EA (1) EA201400447A1 (https=)
IL (1) IL231975A0 (https=)
MX (1) MX2014004326A (https=)
SG (1) SG11201400521PA (https=)
WO (1) WO2013053021A1 (https=)
ZA (1) ZA201401776B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107531787B (zh) * 2015-01-27 2022-01-18 拉法医疗有限公司 靶向cd1d的单域抗体
SMT202100564T1 (it) * 2016-04-08 2022-01-10 Adaptimmune Ltd Recettori di cellule t
CA3020555A1 (en) * 2016-04-08 2017-10-12 Adaptimmune Limited T cell receptors
PL3440105T3 (pl) * 2016-04-08 2022-08-29 Immunocore Limited Receptory komórek t
CN108079292A (zh) * 2016-11-23 2018-05-29 苏州盛迪亚生物医药有限公司 一种抗pd-1抗体在制备治疗肝癌的药物中的用途
EP3595683A1 (en) * 2017-03-15 2020-01-22 Orca Biosystems, Inc. Compositions and methods for hematopoietic stem cell transplants
WO2020060406A1 (en) * 2018-09-19 2020-03-26 Lava Therapeutics B.V. Novel bispecific antibodies for use in the treatment of hematological malignancies
GB201820006D0 (en) * 2018-12-07 2019-01-23 Lifearc Humanised anti-IL17BR antibody
US11725052B2 (en) * 2020-08-18 2023-08-15 Cephalon Llc Anti-PAR-2 antibodies and methods of use thereof
EP4263612A4 (en) * 2020-12-18 2025-04-02 Bioardis LLC Mesothelin binding molecules and uses thereof
CA3265218A1 (en) 2022-08-18 2024-02-22 Immunocore Ltd MAGE A4 SPECIFIC T LYMPHOCYTE RECEPTOR FUSION PROTEINS
CN116217704B (zh) * 2022-10-25 2025-08-15 南京医科大学 一种抑制肝细胞凋亡的表面分子及其应用
CN120548186A (zh) * 2022-12-21 2025-08-26 得克萨斯大学体系董事会 功能增强的表达cd3和itcr的工程化的自然杀伤细胞用于过继免疫疗法
WO2024226794A1 (en) * 2023-04-26 2024-10-31 The Trustees Of Indiana University Composition and methods for treatment of spinal cord injury and traumatic brain injury

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000002923A1 (en) * 1998-07-09 2000-01-20 Nickoloff Brian J Method of treating disorders by modulating the interaction of natural killer receptors on t cells with their respective ligands
AU2003234443A1 (en) * 2002-05-01 2003-11-17 Beth Israel Deaconess Medical Center Use of anti-cd1 antibodies for the modulation of immune responses
US20100035843A1 (en) * 2007-02-12 2010-02-11 The General Hospital Corporation Methods for attenuating allergen-induced airway hyperreactivity using cd1d dependent antagonists
US8012484B2 (en) * 2007-04-12 2011-09-06 University Of Virginia Patent Foundation Method of treating ischemia reperfusion injury by inhibiting NKT cell activity

Also Published As

Publication number Publication date
CA2850961A1 (en) 2013-04-18
SG11201400521PA (en) 2014-08-28
EP2766042A4 (en) 2015-05-27
CN104144700B (zh) 2016-10-19
BR112014008691A2 (pt) 2017-06-13
ZA201401776B (en) 2016-01-27
AU2012323781A8 (en) 2015-05-14
KR20140108520A (ko) 2014-09-11
AU2012323781B2 (en) 2015-04-23
NZ622050A (en) 2016-07-29
AU2012323781B8 (en) 2015-05-14
EA201400447A1 (ru) 2014-09-30
WO2013053021A1 (en) 2013-04-18
IL231975A0 (en) 2014-05-28
JP2015502915A (ja) 2015-01-29
EP2766042A1 (en) 2014-08-20
US20140286957A1 (en) 2014-09-25
CN104144700A (zh) 2014-11-12
AU2012323781A1 (en) 2014-03-27

Similar Documents

Publication Publication Date Title
MX2014004326A (es) Anticuerpos a cd1d.
IL262073B (en) Antibody drug conjugates (adc) that bind to 191p4d12 proteins
MX341076B (es) Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados.
EA201590247A1 (ru) Антитела к siglec-15
EA201400579A1 (ru) Антитела к il-36r
PH12014501164A1 (en) Anti-cd98 antibodies and methods of use thereof
PH12013500810B1 (en) Anti-il-23 antibodies
EP2566890A4 (en) ANTI-PAI-1 ANTIBODIES AND METHOD FOR THEIR USE
PH12013500933A1 (en) Methods and compositions for neural disease immunotherapy
MX2013011479A (es) Anticuerpos anti-fgfr4 y metodos de uso.
PH12014501427B1 (en) Anti-phf-tau antibodies and their uses
PH12014502406A1 (en) Anti-il-23p19 antibodies
PH12014500841B1 (en) ANTI-HtrA1 ANTIBODIES AND METHODS OF USE
PH12013501255A1 (en) Anti-notch1 antibodies
WO2012109238A3 (en) Methods for increasing immune responses using agents that directly bind to and activate ire-1
MX347247B (es) Agentes capaces de la activación de células t regulatorias cd4+cd25+ y su uso en el tratamiento de enfermedad.
GB201109238D0 (en) Antibodies
SG10201807059QA (en) Agents for influenza neutralization
MX2014001766A (es) Anticuerpos de neuregulina y sus usos.
BR112014025560A2 (pt) anticorpos anti-pdgf-c
PH12013500432A1 (en) Anti-vegfr-3 antibody compositions
WO2012095432A3 (en) Tlr3 binding agents
UA110051C2 (uk) Антитіло, яке зв'язує tgf-альфа та епірегулін
MX2015004892A (es) Metodos y composiciones que se relacionan con anticuerpos de receptor anti-il-21.
WO2012166659A3 (en) Anti-emr1 antibodies